YCANTH (NDA212905)- (0.7%)

Generic Name	CANTHARIDIN	Innovator	VERRICA PHARMS
Dosage	0.7%
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2038-Aug-22	NCE Excl Expiry	2028-Jul-21
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.7%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of YCANTH